Navigation Links
AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
Date:5/16/2013

REDWOOD CITY, Calif., May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King , President and CEO, will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York, NY.  The presentation is scheduled for Wednesday, May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT.

The presentation will be webcast live and can be accessed through the Investors page followed by referring to the Event Calendar page at www.acelrx.com.  For those not available to listen to the live broadcast, a replay of the presentation will be archived and available through www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced results from two Phase 3 clinical trials for the NanoTab System, and a third Phase 3 study has completed enrollment, with data expected in the second quarter of 2013.  A New Drug Application submission is planned for the third quarter of 2013. AcelRx recently announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the release and anticipated timing of additional NanoTab System clinical trial data, anticipated timing of completion of AcelRx Pharmaceuticals' current clinical trials, submission of the NDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo:  http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
2. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
3. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
4. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
5. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
6. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
7. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
8. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. AcelRx Pharmaceuticals Provides Clinical Trial Updates
10. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
11. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2019)... ... 15, 2019 , ... Men’s Health Memorial will celebrate the grand opening of ... how to regain their strength and vitality. , “While many men may notice ... something about it is not always easy,” said Robert A. Ochoa, MD, Medical Director ...
(Date:8/15/2019)... ... August 15, 2019 , ... Inc. magazine ... most prestigious ranking of the nation’s fastest-growing private companies. The list represents a ... segment—its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, ...
(Date:8/14/2019)... ... 14, 2019 , ... Bach Pharma, Inc., a company based ... platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative diseases including ... multiple animal studies have proven that GVT has the potential to help millions ...
Breaking Medicine Technology:
(Date:8/14/2019)... ... ... While it is commonly understood that good nutrition promotes general health, consumers are becoming ... in some cases, reverse certain medical conditions, according to health and wellness research by ... to manage a health or medical condition by making healthy food and beverage choices. ...
(Date:8/12/2019)... ... August 12, 2019 , ... Cryotherapy has recently been the ... the Oakland Raiders. However, the cause of Brown’s injury was not due to cryotherapy, ... cryotherapy session. Numerous NFL teams, such as the Dallas Cowboys, the Washington Redskins, the ...
(Date:8/12/2019)... ... August 12, 2019 , ... Injured veterans from ... received through the 4th annual Lockton Warfighter Sports Charity Challenge being held on ... , Participating in the event again this year will be fifty wounded warfighters ...
(Date:8/9/2019)... ... August 09, 2019 , ... Advanced Clinical, a clinical ... into Europe’s third largest pharmaceutical market with the recent opening of a new, ... now completes the organization’s thorough coverage of Western Europe. Access to an extensive ...
(Date:8/9/2019)... (PRWEB) , ... August 09, 2019 , ... ... tools, has recently launched the EasyEyes v1.0 brightness adjusting software which helps in ... society, with users staring at the screens for several hours per day. This ...
Breaking Medicine News(10 mins):